Biotalys Reports Full-Year 2024 Financial Results and Business Highlights

Press release – regulated information Continued to work closely with European and U.S. regulators on the regulatory review of its first candidate biofungicide EVOCA™*, earning recommendation for EU approval by the Dutch CTGB in January 2025 on the back of the approval of large-scale demonstration trials in the NetherlandsProgressed product pipeline with initial field trials for BioFun-6 showing strong results and highlighting the increased potency of the tested candidate Closed...

Ghent, 19/03/2025 (informazione.news - comunicati stampa - cibi e bevande)

Press release – regulated information

Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced key business achievements and consolidated financial results for 2024, prepared in accordance with IFRS as adopted by the European Union, and an outlook for 2025. The annual report, including the full financial report, will be published on the company's website on 21 March 2025.

Kevin Helash, Chief Executive Officer of Biotalys, stated : “Biotalys continued to lead the charge toward creating effective and sustainable crop protection products in 2024. While we worked closely with regulators to progress the potential approval for innovative protein-based biocontrols like EVOCA, we also strengthened our platform, pipeline, partnerships, and team. Additionally, we optimized capital resources last year, achieving a significant reduction in operating expenses while strengthening our balance sheet through a successful private placement. Looking ahead, we plan to further advance our product portfolio and develop novel modes of action, as well as expand options to scale and produce our biobased solutions.”

Highlights
In 2024, Biotalys continued to cement its role as a primary innovator in the biocontrol space by advancing its technology platform and product development pipeline.

Product Pipeline:

Operations and Leadership:

Outlook for 2025

Detailed financial review for 2024

Consolidated statements of profit and loss

THE FINANCIAL TABLES ARE IN THE PDF DOCUMENTS ATTACHED TO THIS PRESS RELEASE

Auditor Statement
The consolidated financial statements have been prepared in accordance with IFRS, as adopted by the EU. The financial information included in this press release is an extract from the full IFRS consolidated financial statements, which will be published on 21 March 2025. The statutory auditor, Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises, represented by Pieter-Jan Van Durme, has confirmed that its audit procedures have not revealed any material adjustment that should be made in the accounting information included in this press release.

Financial calendar

Live webcast and conference call
Company management will host a live webcast in English to discuss its full year 2024 financial results and business highlights, today 19 March 2025 at 15:00 CET / 14:00 GMT / 09:00 AM ET. The webcast can be accessed via the following link: https://edge.media-server.com/mmc/p/sjcyf8dw.

Dial-in details: to ask questions live to management, please register for the conference call via the following link: https://register-conf.media-server.com/register/BIe6b7d26b684849d6a561c7bc6625c71f.

A recording of the webcast will be available after the event on the Biotalys investor website: https://www.biotalys.com/investors/financial-information.

* EVOCA™: Pending regulatory review. This product is not currently registered for sale or use in the European Union, the United States, or elsewhere and is not being offered for sale and no assurance can be given if and when registration will be obtained.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: IR@biotalys.com

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company's website.

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys' actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Attachments